$PFE

Trump policy announcements now drive S&P 500 swings. Five trading days account for entire 19% 2025 gain; excluding them shows 2.7% loss.

Omics clinical trials market grows 8.8% annually from $31.71B in 2025 to $47.78B by 2030, driven by personalized medicine demand and AI advances.

Mental health clinical trials market projected to grow 51% from $3.23B (2025) to $4.89B (2030) at 8.6% CAGR, driven by digital innovation and Asia-Pacific expansion.

Levicept will present Phase II data for LEVI-04 at OARSI 2026, showing pain relief comparable to NSAIDs in 518-patient trial published in The Lancet.

Over 65 pharma companies advance 75+ COPD drugs, shifting from traditional bronchodilators to targeted biologics as AstraZeneca's tozorakimab validates new approaches.

Inhibrx is fielding takeover interest from major pharma for cancer drug INBRX-106 in potential $9B spin-off; stock surges 39.86%.

Nurix Therapeutics unveils preclinical data showing protein degradation pipeline effectiveness, with NRX-0305 achieving 142% lifespan extension in melanoma models.

Pfizer's experimental monthly GLP-1 injection threatens to disrupt the weight-loss market dominated by Novo Nordisk and Eli Lilly, potentially triggering price competition.

Bispecific antibody market projected to reach $60 billion by 2031 from $16 billion in 2025, with 550+ clinical trials and 18 approved drugs driving sector transformation.

$LLY surged 1,100% in ten years via GLP-1 drugs, but 39x P/E ratio and patent risks loom.

Over 100 pharmaceutical companies compete to develop 120+ NSCLC pipeline drugs, with 30+ in late-stage trials. Precision oncology advances drive innovation in biomarker-selected populations.

Three blue-chip stocks with 6%+ dividend yields could generate $1,500 annually on $8,000 per position despite recent headwinds.

CSPC market projected to surge from $5.14B (2025) to $11.75B (2036), driven by aging populations, new drug approvals, and emerging therapies.

Atopic dermatitis drug market projected to grow from $8.5B (2023) to $21.5B (2033) at 9.8% CAGR, fueled by seven late-stage pipeline therapies.

Global atopic dermatitis market projected to grow from $10.8B in 2023 to $26.2B by 2033, driven by seven late-stage pipeline drugs and expanded treatment options.

Crohn's Disease drug market projected to grow 45% to $13.8B by 2032, driven by eight new therapies with novel mechanisms of action reshaping competition.

Serina's Chief Development Officer to present novel POZ-based lipid nanoparticles that eliminate PEG immunogenicity issues, showing no antibody response in preclinical studies.

President Trump's executive order imposes 100% tariffs on imported drugs, exempting 13 companies with MFN agreements and U.S. manufacturing commitments through 2029.

Pfizer and Valneva's Lyme disease vaccine demonstrates 70%+ efficacy in Phase 3 trials, advancing toward potential regulatory approval after decades without preventive options.

Pfizer and Valneva's experimental Lyme disease vaccine demonstrated over 70% efficacy in Phase 3 trials for children and adults aged five and older.